The difficulties in importing reagents and supplies in Brazil made Fiocruz “turn on the yellow alert” in relation to the national manufacture of the Oxford / AstraZeneca vaccine against Covid-19. According to Maurício Zuma, director of Bio-Manguinhos – a Fiocruz unit that produces the immunizing agent – the country’s health crisis has caused foreign airlines to deny flights to Brazil. The information is from Uol.
According to Zuma, the records of deaths and new strains of the disease are the reasons for the resistance of international companies to send flights. Because of this, the production of Fiocruz’s immunizers against covid-19 is at risk, since imported materials are considered fundamental for the production line.
The director of Bio-Manguinhos also points out that the high demand for these supplies in the international market is another obstacle faced today for the acquisition.
In a note to Uol, Fiocruz admitted difficulties with international transport and cited other reasons for the cancellation of flights. “The airlines have a reduced network and are facing constant problems with a lack of crew. This scenario generates an increase in the deadlines for receiving cargo, with delays and rescheduling of flights. Boarding schedules are postponed, flights are canceled or we experience a lack of space for our aircraft cargo ”, says the statement.
+ Helena Rizzo, from Maní, is the new MasterChef Brasil judge
+ Contran extends deadline for renewal of CNH
+ Brazilian chef has intimate photos leaked after debuting on reality show
+ Video: step by step how to make Easter egg
+ Juju Salimeni poses topless for a new shoot and wins praise: “Perfection”
+ 5 benefits of intermittent fasting in addition to losing weight
+ Cinema, sex and the city
+ Trick to squeeze lemons becomes a craze on social media
+ Study reveals the healthiest method for cooking rice
+ Shark is captured in MA with remains of young people missing in the stomach
+ Giant anacondas are caught on expeditions of photographers in MS
Get the latest news delivered to your inbox
Follow us on social media networks